​

Johnson & Johnson (JNJ) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

JNJ Stock Forecast

Johnson & Johnson stock forecast is as follows: an average price target of $175.13 (represents a 19.62% upside from JNJ’s last price of $146.41) and a rating consensus of 'Buy', based on 21 wall street analysts offering a 1-year stock forecast.

JNJ Price Target

The average price target for Johnson & Johnson (JNJ) is $175.13 based on 1-year price targets from 21 Wall Street analysts in the past 3 months, with a price target range of $215.00 to $150.00. This represents a potential 19.62% upside from JNJ's last price of $146.41.

JNJ Analyst Ratings

Buy

According to 21 Wall Street analysts, Johnson & Johnson's rating consensus is 'Buy'. The analyst rating breakdown for JNJ stock is 0 'Strong Buy' (0.00%), 11 'Buy' (52.38%), 10 'Hold' (47.62%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Johnson & Johnson Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 16, 2024Chris ShibutaniGoldman Sachs$159.00$164.28-3.21%8.60%
Oct 16, 2024Terence FlynnMorgan Stanley$175.00$164.106.64%19.53%
Oct 16, 2024Shagun SinghRBC Capital$181.00$164.1010.30%23.63%
Oct 16, 2024Joanne WuenschCitigroup$185.00$164.1012.74%26.36%
Oct 15, 2024Larry BiegelsenWells Fargo$166.00$164.101.16%13.38%
Oct 15, 2024Rick WiseStifel Nicolaus$170.00$164.103.60%16.11%
Oct 15, 2024Joanna WuenschCitigroup$180.00$163.779.91%22.94%
Oct 14, 2024Louise ChenCantor Fitzgerald$215.00$161.6033.04%46.85%
Jul 23, 2024Narumi NakagiriJohnson Rice$150.00$154.24-2.75%2.45%
Jul 17, 2024Rick WiseStifel Nicolaus$160.00$157.161.81%9.28%
May 30, 2024Chris ShibutaniJohnson Rice$160.00$144.4410.77%9.28%
May 30, 2024Chris ShibutaniGoldman Sachs$160.00$144.4110.79%9.28%
May 22, 2024Danielle AntalffyUBS$180.00$152.3418.16%22.94%
Apr 18, 2024Morten HerholdtJohnson Rice$170.00$145.0817.18%16.11%
Apr 17, 2024Louise ChenJohnson Rice$215.00$144.3248.97%46.85%
Apr 17, 2024Shagun SinghRBC Capital$175.00$144.4521.15%19.53%
Apr 16, 2024Rick WiseStifel Nicolaus$155.00$144.457.30%5.87%
Mar 27, 2024Terence FlynnMorgan Stanley$169.00$155.778.49%15.43%
Mar 27, 2024Jayson BedfordRaymond James$175.00$155.7712.35%19.53%
Dec 28, 2023Larry BiegelsenWells Fargo$163.00$156.354.25%11.33%
Dec 28, 2023Jayson BedfordRaymond James$110.00$156.35-29.65%-24.87%
Oct 05, 2023Shagun SinghJohnson Rice$178.00$157.2413.20%21.58%
Jul 21, 2023Trung HuynhJohnson Rice$175.00$170.452.67%19.53%
May 24, 2023John RansomRaymond James$90.00$156.60-42.53%-38.53%
Dec 12, 2022Citigroup$205.00$176.1716.36%40.02%
Dec 06, 2022Morgan Stanley$176.00$178.79-1.56%20.21%
Dec 01, 2022Morgan Stanley$178.00$178.49-0.27%21.58%
Jul 21, 2022UBS$180.00$170.715.44%22.94%
Jul 20, 2022Steve ChesneyAtlantic Equities$165.00$170.71-3.34%12.70%
Jul 20, 2022Larry BiegelsenWells Fargo$195.00$170.7114.23%33.19%
Jul 20, 2022Leerink Partners$194.00$170.8613.54%32.50%
Jul 20, 2022Raymond James$192.00$171.6911.83%31.14%
Jul 20, 2022Citigroup$201.00$171.6917.07%37.29%
Jul 08, 2022Morgan Stanley$174.00$178.50-2.52%18.84%
Apr 20, 2022Citigroup$210.00$183.5114.44%43.43%
Apr 20, 2022Raymond James$196.00$183.466.84%33.87%
Apr 20, 2022Credit Suisse$205.00$182.6412.24%40.02%
Apr 18, 2022Jayson BedfordRaymond James$195.00$177.669.76%33.19%
Apr 11, 2022Matthew HarrisonMorgan Stanley$173.00$179.84-3.80%18.16%
Jan 28, 2022Florent CespedesSociete Generale$177.00$171.793.03%20.89%
Jan 26, 2022Chris ShibutaniGoldman Sachs$163.00$168.38-3.20%11.33%
Dec 29, 2021Matt MiksicCredit Suisse$200.00$170.4617.33%36.60%
Jul 22, 2021Kevin CaliendoUBS$183.00$166.809.71%24.99%
Jul 22, 2021David ToungArgus Research$190.00$166.8013.91%29.77%

The latest Johnson & Johnson stock forecast, released on Oct 16, 2024 by Chris Shibutani from Goldman Sachs, set a price target of $159.00, which represents a -3.21% decrease from the stock price at the time of the forecast ($164.28), and a 8.60% increase from JNJ last price ($146.41).

Johnson & Johnson Price Target by Period

1M3M12M
# Anlaysts-821
Avg Price Target-$178.88$170.14
Last Closing Price$146.41$146.41$146.41
Upside/Downside-100.00%22.18%16.21%

In the current month, the average price target of Johnson & Johnson stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Johnson & Johnson's last price of $146.41. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 16, 2024Bank of America SecuritiesNeutralNeutralHold
Oct 15, 2024Wells FargoEqual-WeightEqual-WeightHold
Oct 15, 2024BarclaysEqual-WeightEqual-WeightHold
Oct 15, 2024CitigroupBuyBuyHold
Oct 14, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Oct 14, 2024Cantor FitzgeraldOverweightOverweightHold
Oct 14, 2024Cowen & Co.BuyBuyHold
Oct 14, 2024BMO CapitalMarket PerformMarket PerformHold
Oct 14, 2024Johnson RiceNeutralNeutralHold
Oct 10, 2024RBC CapitalBuyBuyHold
Oct 08, 2024Goldman SachsNeutralNeutralHold
Oct 08, 2024RBC CapitalOutperformOutperformHold
Sep 06, 2024Johnson RiceOverweightOverweightHold
Sep 06, 2024BarclaysEqual-WeightEqual-WeightHold
Sep 06, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Sep 03, 2024RBC CapitalBuyBuyHold
Jul 30, 2024RBC CapitalBuyBuyHold
Jul 23, 2024Johnson RiceOverweightNeutralDowngrade
Jul 18, 2024RBC CapitalOutperformOutperformHold
Jul 18, 2024Cowen & Co.BuyBuyHold
Jul 17, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Jul 09, 2024Goldman SachsNeutralNeutralHold
Jun 28, 2024Johnson RiceOverweightOverweightHold
Jun 17, 2024RBC CapitalBuyBuyHold
Jun 17, 2024RBC CapitalOutperformOutperformHold
Jun 11, 2024Bank of America SecuritiesNeutralNeutralHold
Jun 05, 2024CitigroupBuyBuyHold
May 29, 2024Wells FargoEqual-WeightEqual-WeightHold
May 22, 2024RBC CapitalBuyBuyHold
May 22, 2024Morgan StanleyUnderperformUnderperformHold
May 22, 2024RBC CapitalOutperformOutperformHold
May 22, 2024UBSBuyBuyHold
Apr 18, 2024Johnson RiceOverweightBuyUpgrade
Apr 18, 2024Johnson RiceOverweightNegativeUpgrade
Apr 17, 2024Johnson RiceOverweightOverweightHold
Apr 17, 2024Johnson RiceNeutralNeutralHold
Apr 17, 2024RBC CapitalOutperformOutperformHold
Apr 17, 2024Bank of America SecuritiesNeutralNeutralHold
Apr 15, 2024RBC CapitalEqual-WeightEqual-WeightHold
Mar 27, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Mar 27, 2024Johnson RiceHoldHoldHold
Mar 27, 2024Raymond JamesOutperformOutperformHold
Feb 28, 2024Wells FargoBuyBuyHold
Jan 24, 2024Wells FargoBuyBuyHold
Dec 28, 2023Wells FargoOverweightEqual-WeightDowngrade
Dec 28, 2023Argus ResearchBuyBuyHold
Dec 11, 2023Johnson RiceBuyBuyHold
Dec 01, 2023UBSNeutralBuyUpgrade
Oct 05, 2023Johnson RiceBuyOutperformInitialise
Aug 04, 2023Atlantic EquitiesNeutralNeutralHold
Jul 24, 2023Raymond JamesOutperformOutperformHold
Jul 21, 2023Johnson RiceBuyBuyHold
May 24, 2023SVB LeerinkOutperformOutperformHold
May 24, 2023Credit SuisseOutperformOutperformHold
May 24, 2023Raymond JamesOutperformOutperformHold
Apr 10, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Mar 01, 2023GuggenheimNeutralInitialise
Dec 12, 2022CitigroupBuyBuyHold
Dec 01, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Oct 18, 2022Cantor FitzgeraldOverweightOverweightHold
Oct 12, 2022NeedhamBuyBuyHold
Sep 29, 2022SVB LeerinkOutperformOutperformHold
Sep 12, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Aug 11, 2022Johnson RicePositivePositiveHold
Jul 30, 2022Johnson RiceOutperformOutperformHold
Jul 21, 2022UBSNeutralNeutralHold
Jul 20, 2022SVB LeerinkOutperformOutperformHold
Jul 20, 2022Atlantic EquitiesNeutralNeutralHold
Jul 20, 2022Raymond JamesOutperformOutperformHold
Jul 20, 2022CitigroupBuyBuyHold
Jul 13, 2022Wells FargoOverweightOverweightHold
Jul 08, 2022Morgan StanleyEqual-WeightEqual-WeightHold
May 17, 2022CitigroupBuyBuyHold
Apr 18, 2022Raymond JamesOutperformOutperformHold
Jan 28, 2022Societe GeneraleHoldHoldHold
Jan 26, 2022CFRABuyBuyHold
Jan 26, 2022Goldman SachsNeutralNeutralHold
Jan 02, 2022Credit SuisseOutperformOutperformHold
Dec 17, 2021Johnson RiceNeutralInitialise
Dec 05, 2021Credit SuisseOutperformOutperformHold

Johnson & Johnson's last stock rating was published by Bank of America Securities on Oct 16, 2024. The company gave JNJ a "Neutral" rating, the same as its previous rate.

Johnson & Johnson Financial Forecast

Johnson & Johnson Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$23.71B$21.35B$25.53B$24.75B$24.80B$23.79B$24.02B$23.43B$22.48B$23.34B$23.31B$22.32B-$21.08B$18.34B$20.69B$20.75B$20.73B
Avg Forecast$24.92B$24.29B$24.21B$23.20B$23.24B$23.19B$22.93B$22.03B$22.46B$22.17B$22.33B$21.40B$21.02B$21.04B$24.63B$23.60B$23.88B$23.36B$23.77B$23.62B$25.28B$23.64B$22.49B$21.98B$21.66B$20.20B$17.61B$19.73B$20.80B$20.08B
High Forecast$25.21B$24.56B$24.48B$23.46B$23.50B$23.45B$23.19B$22.12B$22.91B$22.19B$22.33B$21.41B$21.06B$21.27B$24.91B$23.87B$24.15B$23.66B$24.07B$23.93B$25.60B$23.94B$22.78B$22.26B$21.94B$20.46B$17.83B$19.98B$21.06B$20.34B
Low Forecast$24.70B$24.07B$23.99B$22.99B$23.03B$22.98B$22.72B$21.95B$22.22B$22.15B$22.33B$21.40B$21.01B$20.84B$24.41B$23.39B$23.66B$23.10B$23.51B$23.36B$24.99B$23.38B$22.24B$21.74B$21.42B$19.97B$17.41B$19.51B$20.57B$19.86B
# Analysts222211141264484443333444991499158
Surprise %------------1.13%1.01%1.04%1.05%1.04%1.02%1.01%0.99%0.89%0.99%1.04%1.02%-1.04%1.04%1.05%1.00%1.03%

Johnson & Johnson's average Quarter revenue forecast for Mar 24 based on 4 analysts is $21.40B, with a low forecast of $21.40B, and a high forecast of $21.41B. JNJ's average Quarter revenue forecast represents a -9.72% decrease compared to the company's last Quarter revenue of $23.71B (Dec 23).

Johnson & Johnson EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts222211141264484443333444991499158
EBITDA------------$5.50B$6.26B$6.97B$6.73B$6.74B$6.38B$6.26B$7.11B$3.67B$5.68B$8.54B$9.39B-$6.26B$5.71B$8.58B$6.12B$3.42B
Avg Forecast$8.42B$8.20B$8.17B$7.83B$7.85B$7.83B$7.74B$7.44B$7.59B$7.49B$7.54B$10.68B$7.10B$7.10B$8.32B$9.71B$8.10B$7.81B$7.95B$8.83B$8.46B$7.91B$7.52B$8.02B$7.25B$6.76B$5.89B$7.29B$6.96B$6.72B
High Forecast$8.51B$8.29B$8.27B$7.92B$7.94B$7.92B$7.83B$7.47B$7.74B$7.49B$7.54B$12.81B$7.11B$7.18B$8.41B$11.65B$9.72B$7.91B$8.05B$10.59B$8.56B$8.01B$7.62B$9.63B$7.34B$6.84B$5.97B$8.75B$7.05B$6.80B
Low Forecast$8.34B$8.13B$8.10B$7.76B$7.78B$7.76B$7.67B$7.41B$7.50B$7.48B$7.54B$8.54B$7.10B$7.04B$8.24B$7.77B$6.48B$7.73B$7.86B$7.06B$8.36B$7.82B$7.44B$6.42B$7.17B$6.68B$5.82B$5.84B$6.88B$6.64B
Surprise %------------0.77%0.88%0.84%0.69%0.83%0.82%0.79%0.81%0.43%0.72%1.14%1.17%-0.93%0.97%1.18%0.88%0.51%

4 analysts predict JNJ's average Quarter EBITDA for Mar 24 to be $10.68B, with a high of $12.81B and a low of $8.54B. This is 94.20% upper than Johnson & Johnson's previous annual EBITDA (Dec 23) of $5.50B.

Johnson & Johnson Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts222211141264484443333444991499158
Net Income------------$3.52B$26.03B$5.14B$-68.00M$4.74B$4.46B$4.81B$5.15B$1.74B$3.67B$6.28B$6.20B-$3.55B$3.63B$5.80B$4.01B$1.75B
Avg Forecast$6.81B$6.42B$6.85B$6.53B$6.13B$6.46B$6.59B$6.42B$4.90B$5.36B$6.58B$7.21B$5.54B$6.11B$6.35B$6.56B$5.31B$6.01B$6.16B$5.96B$5.14B$5.71B$5.56B$5.42B$4.42B$4.80B$3.63B$4.93B$4.54B$4.88B
High Forecast$6.91B$6.51B$6.95B$6.62B$6.22B$6.55B$6.69B$6.49B$5.15B$5.39B$6.58B$8.66B$5.61B$6.20B$6.45B$7.87B$6.37B$6.11B$6.26B$7.15B$5.22B$5.80B$5.65B$6.50B$4.50B$4.88B$3.69B$5.91B$4.61B$4.96B
Low Forecast$6.73B$6.34B$6.77B$6.45B$6.06B$6.38B$6.51B$6.32B$4.76B$5.32B$6.58B$5.77B$5.49B$6.04B$6.28B$5.25B$4.25B$5.93B$6.07B$4.77B$5.06B$5.63B$5.48B$4.34B$4.36B$4.73B$3.58B$3.94B$4.47B$4.81B
Surprise %------------0.64%4.26%0.81%-0.01%0.89%0.74%0.78%0.86%0.34%0.64%1.13%1.14%-0.74%1.00%1.18%0.88%0.36%

Johnson & Johnson's average Quarter net income forecast for Mar 24 is $7.21B, with a range of $5.77B to $8.66B. JNJ's average Quarter net income forecast represents a 104.92% increase compared to the company's last Quarter net income of $3.52B (Dec 23).

Johnson & Johnson SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts222211141264484443333444991499158
SG&A------------$6.51B$5.40B$6.67B$6.14B$7.15B$6.09B$6.23B$5.94B$6.46B$6.00B$6.07B$5.43B-$5.43B$4.99B$5.20B$6.04B$5.37B
Avg Forecast$6.32B$6.16B$6.14B$5.88B$5.89B$5.88B$5.81B$5.59B$5.69B$5.62B$5.66B$6.48B$5.33B$5.33B$6.24B$5.89B$7.99B$5.92B$6.03B$5.35B$6.41B$5.99B$5.70B$4.86B$5.49B$5.12B$4.46B$4.42B$5.27B$5.09B
High Forecast$6.39B$6.23B$6.21B$5.95B$5.96B$5.95B$5.88B$5.61B$5.81B$5.63B$5.66B$7.77B$5.34B$5.39B$6.32B$7.06B$9.59B$6.00B$6.10B$6.42B$6.49B$6.07B$5.77B$5.84B$5.56B$5.19B$4.52B$5.31B$5.34B$5.16B
Low Forecast$6.26B$6.10B$6.08B$5.83B$5.84B$5.83B$5.76B$5.56B$5.63B$5.62B$5.66B$5.18B$5.33B$5.28B$6.19B$4.71B$6.40B$5.85B$5.96B$4.28B$6.34B$5.93B$5.64B$3.89B$5.43B$5.06B$4.41B$3.54B$5.21B$5.03B
Surprise %------------1.22%1.01%1.07%1.04%0.89%1.03%1.03%1.11%1.01%1.00%1.07%1.12%-1.06%1.12%1.18%1.15%1.06%

Johnson & Johnson's average Quarter SG&A projection for Mar 24 is $6.48B, based on 4 Wall Street analysts, with a range of $5.18B to $7.77B. The forecast indicates a -0.57% fall compared to JNJ last annual SG&A of $6.51B (Dec 23).

Johnson & Johnson EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts222211141264484443333444991499158
EPS------------$1.35$10.81$1.98$-0.03$1.80$1.70$1.83$1.96$0.66$1.39$2.38$2.35-$1.35$1.38$2.20$1.52$0.67
Avg Forecast$2.81$2.64$2.82$2.69$2.52$2.66$2.71$2.64$2.02$2.21$2.71$2.66$2.28$2.52$2.62$2.50$2.24$2.48$2.54$2.59$2.12$2.35$2.29$2.34$1.82$1.98$1.49$2.02$1.87$2.01
High Forecast$2.85$2.68$2.86$2.73$2.56$2.70$2.75$2.67$2.12$2.22$2.71$2.66$2.31$2.55$2.66$2.54$2.27$2.52$2.58$2.63$2.15$2.39$2.33$2.38$1.85$2.01$1.52$2.05$1.90$2.04
Low Forecast$2.77$2.61$2.79$2.66$2.49$2.63$2.68$2.60$1.96$2.19$2.71$2.65$2.26$2.49$2.59$2.47$2.21$2.44$2.50$2.55$2.09$2.32$2.26$2.30$1.79$1.95$1.47$1.99$1.84$1.98
Surprise %------------0.59%4.30%0.76%-0.01%0.80%0.69%0.72%0.76%0.31%0.59%1.04%1.01%-0.68%0.92%1.09%0.82%0.33%

According to 4 Wall Street analysts, Johnson & Johnson's projected average Quarter EPS for Mar 24 is $2.66, with a low estimate of $2.65 and a high estimate of $2.66. This represents a 96.72% increase compared to JNJ previous annual EPS of $1.35 (Dec 23).

Johnson & Johnson Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
MRKMerck$100.06$135.8335.75%Buy
LLYEli Lilly and Company$778.62$1.03K31.80%Buy
AMGNAmgen$265.95$338.2227.17%Buy
PFEPfizer$26.43$32.8324.21%Hold
ABBVAbbVie$175.38$211.2020.42%Buy
JNJJohnson & Johnson$146.41$175.1319.62%Buy
GILDGilead Sciences$92.80$87.30-5.93%Buy
BMYBristol-Myers Squibb Company$57.65$50.50-12.40%Hold

JNJ Forecast FAQ

Is Johnson & Johnson a good buy?

Yes, according to 21 Wall Street analysts, Johnson & Johnson (JNJ) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 52.38% of JNJ's total ratings.

What is JNJ's price target?

Johnson & Johnson (JNJ) average price target is $175.13 with a range of $150 to $215, implying a 19.62% from its last price of $146.41. The data is based on 21 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Johnson & Johnson stock go up soon?

According to Wall Street analysts' prediction for JNJ stock, the company can go up by 19.62% (from the last price of $146.41 to the average price target of $175.13), up by 46.85% based on the highest stock price target, and up by 2.45% based on the lowest stock price target.

Can Johnson & Johnson stock reach $200?

JNJ's highest twelve months analyst stock price target of $215 supports the claim that Johnson & Johnson can reach $200 in the near future.

What are Johnson & Johnson's analysts' financial forecasts?

Johnson & Johnson's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $91.39B (high $92.27B, low $90.69B), average EBITDA is $30.86B (high $31.16B, low $30.63B), average net income is $25.6B (high $25.96B, low $25.28B), average SG&A $23.17B (high $23.39B, low $22.99B), and average EPS is $10.54 (high $10.69, low $10.41). JNJ's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $96.61B (high $97.71B, low $95.74B), average EBITDA is $32.63B (high $33B, low $32.33B), average net income is $26.61B (high $27B, low $26.3B), average SG&A $24.49B (high $24.77B, low $24.27B), and average EPS is $10.96 (high $11.12, low $10.83).

Did the JNJ's actual financial results beat the analysts' financial forecasts?

Based on Johnson & Johnson's last annual report (Dec 2023), the company's revenue was $94.94B, beating the average analysts forecast of $90.29B by 5.15%. Apple's EBITDA was $24.02B, missing the average prediction of $32.23B by -25.46%. The company's net income was $17.94B, missing the average estimation of $24.56B by -26.94%. Apple's SG&A was $24.76B, beating the average forecast of $22.79B by 8.66%. Lastly, the company's EPS was $6.86, missing the average prediction of $9.92 by -30.82%. In terms of the last quarterly report (Dec 2023), Johnson & Johnson's revenue was $23.71B, beating the average analysts' forecast of $21.02B by 12.77%. The company's EBITDA was $5.5B, missing the average prediction of $7.1B by -22.54%. Johnson & Johnson's net income was $3.52B, missing the average estimation of $5.54B by -36.44%. The company's SG&A was $6.51B, beating the average forecast of $5.33B by 22.20%. Lastly, the company's EPS was $1.35, missing the average prediction of $2.28 by -40.81%